O Freudenreich

Summary

Affiliation: Brigham and Women's Hospital
Country: USA

Publications

  1. doi Elevated clozapine serum level after treatment with amiodarone
    Jonathan R Stevens
    Dept of Psychiatry, Massachusetts General Hospital, MA 02114, USA
    Psychosomatics 49:255-7. 2008
  2. ncbi Sexual functioning, psychopathology and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 94:119-27. 2007
  3. ncbi Insight into current symptoms of schizophrenia. Association with frontal cortical function and affect
    O Freudenreich
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Acta Psychiatr Scand 110:14-20. 2004
  4. ncbi Drug-induced sialorrhea
    Oliver Freudenreich
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Drugs Today (Barc) 41:411-8. 2005
  5. ncbi Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations
    O Freudenreich
    MGH Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 106:323-30. 2002
  6. ncbi Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight
    Oliver Freudenreich
    MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:1372-6. 2004
  7. ncbi A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain
    D C Henderson
    The Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 115:101-5. 2007
  8. ncbi An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 113:142-7. 2006
  9. doi A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 119:457-65. 2009
  10. doi Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia
    X Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 127:217-26. 2013

Detail Information

Publications49

  1. doi Elevated clozapine serum level after treatment with amiodarone
    Jonathan R Stevens
    Dept of Psychiatry, Massachusetts General Hospital, MA 02114, USA
    Psychosomatics 49:255-7. 2008
  2. ncbi Sexual functioning, psychopathology and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 94:119-27. 2007
    ..The present study was to characterize relationships among sexual functioning, schizophrenia symptoms and quality of life measures. In addition, sexual functioning was compared among patients treated with different antipsychotic agents...
  3. ncbi Insight into current symptoms of schizophrenia. Association with frontal cortical function and affect
    O Freudenreich
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Acta Psychiatr Scand 110:14-20. 2004
    ..Examine whether frontal lobe dysfunction or affective experiences correlates with lack of symptom awareness in schizophrenia...
  4. ncbi Drug-induced sialorrhea
    Oliver Freudenreich
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Drugs Today (Barc) 41:411-8. 2005
    ..g., sublingual ipratropium spray); or increase adrenergic tone (e.g., clonidine patch). Recently, botulinum injections into the parotid gland have been used successfully to treat refractory cases...
  5. ncbi Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations
    O Freudenreich
    MGH Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 106:323-30. 2002
    ..To review the literature on efficacy and risks of combining antipsychotics (atypical with atypical or conventional) and suggest a rationale and strategies for future clinical trials...
  6. ncbi Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight
    Oliver Freudenreich
    MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:1372-6. 2004
    ....
  7. ncbi A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain
    D C Henderson
    The Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 115:101-5. 2007
    ..This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine-associated weight gain...
  8. ncbi An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 113:142-7. 2006
    ..We conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia...
  9. doi A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 119:457-65. 2009
    ....
  10. doi Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia
    X Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 127:217-26. 2013
    ..This study examined the effects of adjunctive aripiprazole therapy on metabolism in clozapine-treated patients with schizophrenia...
  11. ncbi Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia
    D C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 113:121-5. 2006
    ..We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism...
  12. ncbi Schizophrenia
    D C Goff
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Clin North Am 85:663-89. 2001
    ..Good medical care is as important for the patient with schizophrenia as for any other patient...
  13. ncbi Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 63:42-8. 2008
    ..We examined whether the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C functional polymorphisms contribute to negative symptoms...
  14. ncbi Dietary intake profile of patients with schizophrenia
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA, USA
    Ann Clin Psychiatry 18:99-105. 2006
    ..We performed a cross-sectional study evaluating the dietary intake of patients with schizophrenia or schizoaffective disorder treated with atypical antipsychotic agents...
  15. ncbi Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:789-97. 2006
    ..Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism...
  16. ncbi Using a medical model with psychotic patients
    Nicholas Kontos
    Am J Psychiatry 163:1646-7; author reply 1647. 2006
  17. ncbi The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
    Ruth S Barr
    The Schizophrenia Program of the Massachusetts General Hospital, Boston, MA 02114, USA
    Neuropsychopharmacology 33:480-90. 2008
    ..These results confirm previous findings that a single dose of nicotine improves attention and suggest that nicotine may specifically improve response inhibition in nonsmokers with schizophrenia...
  18. ncbi Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Psychiatry Res 149:267-71. 2007
    ..An inflammatory process, as reflected by elevated serum levels of CRP, might be associated with more severe psychopathology in a subgroup of patients with schizophrenia...
  19. doi Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 159:140-6. 2008
    ..Evaluating PTSD in patients with schizophrenia could have important implications from both clinical and research perspectives...
  20. ncbi Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 92:90-4. 2007
    ..Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials...
  21. ncbi Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Schizophr Res 92:181-8. 2007
    ..This study examined whether schizophrenia patients homozygous for the risk allele (T/T) exhibit greater impairment in executive function, and determined the extent to which MTHFR's effects on negative symptoms underlie this relationship...
  22. pmc High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
    Michael A Dyer
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Schizophr Res 102:88-95. 2008
    ..In summary, galantamine treatment, at a dose of 32 mg/day, was well tolerated but was not effective as an adjunctive treatment for cognitive deficits in stable nonsmokers with schizophrenia...
  23. ncbi Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, the Division of Infectious Diseases and Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 48:405-11. 2007
    ..However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment...
  24. ncbi A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
    J Clin Psychopharmacol 27:380-6. 2007
    ....
  25. pmc A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuropsychopharmacology 33:465-72. 2008
    ..CX516 was not effective for cognition or for symptoms of schizophrenia when added to clozapine, olanzapine, or risperidone...
  26. ncbi Fronto-hippocampal function during temporal context monitoring in schizophrenia
    Anthony P Weiss
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02129, USA
    Biol Psychiatry 60:1268-77. 2006
    ..Given the importance of the hippocampus and prefrontal cortex (PFC) in this type of memory, we hypothesized that this cognitive deficit stemmed from aberrant fronto-hippocampal activation during memory retrieval...
  27. ncbi Polypharmacy in schizophrenia: a fuzzy concept
    Oliver Freudenreich
    J Clin Psychiatry 64:1132; author reply 1132-3. 2003
  28. ncbi Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series
    Oliver Freudenreich
    J Clin Psychopharmacol 24:98-100. 2004
  29. ncbi Focus on polypharmacy in schizophrenia: does anyone truly benefit?
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Int J Neuropsychopharmacol 7:109-11. 2004
  30. ncbi Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
    ....
  31. ncbi Exacerbation of idiopathic priapism with risperidone-citalopram combination
    Oliver Freudenreich
    J Clin Psychiatry 63:249-50. 2002
  32. ncbi A successful antipsychotic combination trial. Quo Vadis?
    Stephen Stahl
    Acta Psychiatr Scand 110:241-2. 2004
  33. ncbi A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  34. ncbi Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005
    ....
  35. ncbi Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study
    David C Henderson
    Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1116-21. 2005
    ..The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease...
  36. ncbi Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    MGH Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    Psychopharmacology (Berl) 181:358-63. 2005
    ..Schizophrenia is a disorder with cognitive deficits that could stem from cholinergic dysfunction...
  37. ncbi Clinical experience with the management of schizophrenia in the general hospital
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 44:12-23. 2003
    ..In addition to conducting conventional consultations, the consultation psychiatrist in such cases often has a role in educating hospital staff about schizophrenia and in serving as a physician for the mentally ill...
  38. ncbi Treatment noncompliance with orally disintegrating olanzapine tablets
    Oliver Freudenreich
    Can J Psychiatry 48:353-4. 2003
  39. ncbi The ABCs of suicide
    Oliver Freudenreich
    J Clin Psychiatry 66:1194-5. 2005
  40. ncbi The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis
    Oliver Freudenreich
    The Department of Psychiatry, Harvard Medical School, Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Harv Rev Psychiatry 15:189-211. 2007
    ..We describe the illness course and the prognosis for this acute phase of illness and the immediate, postpsychotic period...
  41. ncbi On biology, phenomenology, and pharmacology in schizophrenia
    Oliver Freudenreich
    Am J Psychiatry 161:376; author reply 377-8. 2004
  42. ncbi Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychiatry 65:307-11; quiz 452-3. 2004
    ....
  43. ncbi Checklist psychiatry's effect on psychiatric education
    Oliver Freudenreich
    Am J Psychiatry 161:930; author reply 930. 2004
  44. ncbi Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:1372-7. 2006
    ..This study examined the relationship between fasting serum insulin level and resting energy expenditure (REE) in a cross-sectional sample of nondiabetic schizophrenia patients...
  45. ncbi A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    David C Henderson
    Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
    Am J Psychiatry 162:954-62. 2005
    ..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder...
  46. ncbi Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome
    Oliver Freudenreich
    Am J Psychiatry 163:2019. 2006
  47. ncbi A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005
    ..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation...
  48. ncbi Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
    ..Psychiatrists should address this problem by adopting established strategies for prevention and intervention...
  49. ncbi Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics
    David C Henderson
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA
    J Clin Psychiatry 68:533-41. 2007
    ..0-295.9; referred to as "schizophrenia patients" hereafter) treated with atypical antipsychotic agents...